

Xin-Guang Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3261488/publications.pdf>

Version: 2024-02-01

38
papers

931
citations

430874

18
h-index

477307

29
g-index

40
all docs

40
docs citations

40
times ranked

1156
citing authors

#	ARTICLE	IF	CITATIONS
1	A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. <i>Blood</i> , 2015, 125, 1541-1547.	1.4	100
2	High-dose dexamethasone shifts the balance of stimulatory and inhibitory Fc γ 3 receptors on monocytes in patients with primary immune thrombocytopenia. <i>Blood</i> , 2011, 117, 2061-2069.	1.4	72
3	Chinese guidelines for treatment of adult primary immune thrombocytopenia. <i>International Journal of Hematology</i> , 2018, 107, 615-623.	1.6	63
4	Thrombopoietin receptor agonists shift the balance of Fc γ 3 receptors toward inhibitory receptor IIb on monocytes in ITP. <i>Blood</i> , 2016, 128, 852-861.	1.4	62
5	CD8+ T cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia. <i>Scientific Reports</i> , 2016, 6, 27445.	3.3	61
6	TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy. <i>Immunological Investigations</i> , 2017, 46, 172-182.	2.0	40
7	Low-dose chidamide restores immune tolerance in ITP in mice and humans. <i>Blood</i> , 2019, 133, 730-742.	1.4	40
8	Recent development of ATP-competitive small molecule phosphatidylinositol-3-kinase inhibitors as anticancer agents. <i>Oncotarget</i> , 2017, 8, 7181-7200.	1.8	40
9	High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial. <i>American Journal of Hematology</i> , 2020, 95, 1542-1552.	4.1	39
10	Effector T helper cell populations are elevated in the bone marrow of rheumatoid arthritis patients and correlate with disease severity. <i>Scientific Reports</i> , 2017, 7, 4776.	3.3	36
11	Reproductive and developmental toxicity study of caffeic acid in mice. <i>Food and Chemical Toxicology</i> , 2019, 123, 106-112.	3.6	35
12	Dexamethasone plus oseltamivir versus dexamethasone in treatment-naïve primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e289-e298.	4.6	31
13	Disrupted balance of CD4+ T-cell subsets in bone marrow of patients with primary immune thrombocytopenia. <i>International Journal of Biological Sciences</i> , 2019, 15, 2798-2814.	6.4	30
14	Indirubin modulates CD4 ⁺ T cell homeostasis via PD1/PTEN/AKT signalling pathway in immune thrombocytopenia. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 1885-1898.	3.6	25
15	Decreased expression of interleukin-27 in immune thrombocytopenia. <i>British Journal of Haematology</i> , 2011, 153, 259-267.	2.5	22
16	Advances in immunopathogenesis of adult immune thrombocytopenia. <i>Frontiers of Medicine</i> , 2013, 7, 418-424.	3.4	19
17	CD11c ⁺ CD138 ⁺ autoantibody predicts better rituximab response in ITP. <i>British Journal of Haematology</i> , 2018, 182, 305-307.	2.5	19
18	Low-Dose Decitabine Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction via Modulating PD-1 Methylation in Immune Thrombocytopenia. <i>Frontiers in Immunology</i> , 2021, 12, 630693.	4.8	19

#	ARTICLE	IF	CITATIONS
19	Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia. <i>Cytokine</i> , 2017, 92, 110-117.	3.2	18
20	Soluble fibrinogen like protein 2 (sFGL2), the novel effector molecule for immunoregulation. <i>Oncotarget</i> , 2017, 8, 3711-3723.	1.8	18
21	Immune Thrombocytopenia and B-Cell-Activating Factor/A Proliferation-Inducing Ligand. <i>Seminars in Hematology</i> , 2013, 50, S89-S99.	3.4	16
22	The association between antinuclear antibody and response to rituximab treatment in adult patients with primary immune thrombocytopenia. <i>Hematology</i> , 2020, 25, 139-144.	1.5	14
23	Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia. <i>Blood Advances</i> , 2021, 5, 4087-4101.	5.2	13
24	Tumor Necrosis Factor- α Blockade Corrects Monocyte/Macrophage Imbalance in Primary Immune Thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2021, 121, 767-781.	3.4	12
25	First line treatment of adult patients with primary immune thrombocytopenia: a real-world study. <i>Platelets</i> , 2020, 31, 55-61.	2.3	11
26	Interleukin-37 reduces inflammation and impairs phagocytosis of platelets in immune thrombocytopenia (ITP). <i>Cytokine</i> , 2020, 125, 154853.	3.2	10
27	T helper 17 and T helper 1 cells are increased but regulatory T cells are decreased in subchondral bone marrow microenvironment of patients with rheumatoid arthritis. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 2956-68.	0.0	10
28	Levels and Clinical Significance of Regulatory B Cells and T Cells in Acute Myeloid Leukemia. <i>BioMed Research International</i> , 2020, 2020, 1-6.	1.9	9
29	Interleukin-17A and -17F Gene Polymorphisms in Chinese Population with Chronic Immune Thrombocytopenia. <i>Annals of Clinical and Laboratory Science</i> , 2016, 46, 291-7.	0.2	9
30	Determination of platelet-bound glycoprotein-specific autoantibodies by flow cytometric immunobead assay in primary immune thrombocytopenia. <i>European Journal of Haematology</i> , 2011, 86, 339-346.	2.2	8
31	Platelet autoantibody specificity and response to rhTPO treatment in patients with primary immune thrombocytopenia. <i>British Journal of Haematology</i> , 2021, 194, 191-194.	2.5	8
32	Atorvastatin restores imbalance of cluster of differentiation 4 (CD4) ⁺ T cells in immune thrombocytopenia <i>in vivo</i> and <i>in vitro</i> . <i>British Journal of Haematology</i> , 2023, 201, 530-541.	2.5	7
33	Immune thrombocytopenia during the COVID-19 pandemic. <i>British Journal of Haematology</i> , 2021, 193, 1093-1095.	2.5	6
34	High-Dose Dexamethasone (HD-DXM) Plus Oseltamivir Versus High-Dose Dexamethasone for Treatment of Adult Primary Immune Thrombocytopenia: Interim Analysis of a Prospective, Multicenter, Randomized, Controlled Trial. <i>Blood</i> , 2019, 134, 900-900.	1.4	5
35	Clonal hematopoiesis in primary immune thrombocytopenia. <i>Blood Cancer Journal</i> , 2022, 12, 40.	6.2	2
36	Pathogenesis-oriented approaches for the management of corticosteroid-resistant or relapsed primary immune thrombocytopenia. <i>Open Medicine (Poland)</i> , 2016, 11, 97-100.	1.3	1

#	ARTICLE	IF	CITATIONS
37	Cell-Based Immunotherapy with Different Subsets of Tolerogenic Dendritic Cell in Idiopathic Thrombocytopenic Purpura.. Blood, 2008, 112, 3408-3408.	1.4	0
38	Abnormal Microenvironment of Bone Marrow B Lymphocytes in Patients with Primary Immune Thrombocytopenia. Blood, 2018, 132, 3759-3759.	1.4	0